Winter J H, Fenech A, Bennett B, Douglas A S
Br J Haematol. 1984 Jul;57(3):527-37. doi: 10.1111/j.1365-2141.1984.tb02927.x.
Three patients with familial antithrombin III deficiency underwent a trial of prophylactic antithrombotic therapy with stanozolol. An increase in plasma fibrinolytic activity and antithrombin III was seen. Acute venous thrombosis occurred in two patients; in the first patient thrombosis was precipitated by venography but in the second no precipitating factor was found. Our experience suggests that stanozolol is not a suitable prophylactic agent in patients with familial antithrombin III deficiency.
三名患有家族性抗凝血酶III缺乏症的患者接受了司坦唑醇预防性抗血栓治疗试验。结果发现血浆纤维蛋白溶解活性和抗凝血酶III有所增加。两名患者发生了急性静脉血栓形成；第一名患者的血栓形成是由静脉造影诱发的，但第二名患者未发现诱发因素。我们的经验表明，司坦唑醇并非家族性抗凝血酶III缺乏症患者的合适预防药物。
